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Abstract
Background
In clinical trials, toxicity leading to tenofovir disoproxil fumarate (TDF) discontinuation is rare
(3% by 2 years); however in clinical practice it seems to be higher, particularlywhen TDF is
co-administeredwith ritonavir-boostedprotease inhibitors (PI/r). Aims of this study were to
assess the rate of TDF discontinuations in clinical practice and to identify factors associated
with the risk of stopping TDF.
Methods
All antiretroviral treatment (ART)-naive patients initiating a TDF-based regimenwere
selected from the ICONA Foundation Study cohort. The primaryoutcomewas TDF discon-
tinuation regardless of the reason; secondary outcomemeasures were TDF discontinuation
due to toxicity and selective TDF discontinuation (that is, TDF discontinuation or substitu-
tion, maintaining unchanged the remaining antiretroviral treatment).
Results
3,618 ART-naïve patients were included: 54% starteda PI/r-based and 46% a NNRTI-
based based regimen. Two-hundred-seventy-seven patients discontinued TDF and reintro-
duced ART within 30 days without TDF. The probability of TDF discontinuation regardless
of the reason was of 7.4% (95%CI:6.4–8.5) by 2 years and 14.1% (95%CI:12.2–16.1)by 5
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years. The 5-year KM estimates in the PI/r vs. NNRTI group were 20.4% vs. 7.6%, respec-
tively (log-rank p = 0.0001), for the outcome of stopping regardless of the reason, and
10.7% vs. 4.7% (p = 0.0001) for discontinuation due to toxicity. PI/r use and lower eGFR
were associated with an increased risk of discontinuing TDF.
Conclusion
In our cohort, the frequency of TDF discontinuations was higher than that observed in clini-
cal trials. Co-administration of TDF with PI/r was associated with an increased rate of TDF
discontinuations. Further studies are needed to clarify the mechanisms that might have led
to this outcome.
Background
Antiretroviral therapy (ART) regimens could be associated with a range of toxicities. Although
the incidence of discontinuation because of intolerance/toxicity has declined over time, it
remains the major cause of drug discontinuation.[1] Tenofovir disoproxil fumarate (TDF) is a
widely prescribed nucleotide reverse transcriptase inhibitor (NRTI) for HIV-1 infection. Possi-
ble TDF adverse events include renal tubule damage, Fanconi’s syndrome, nephrogenic diabe-
tes insipidus and osteopenia/osteoporosis. Although the incidence of renal disease can be
reduced by ART,[2] current use and cumulative exposure to TDF have been associated with
estimated glomerular filtration rate (eGFR) reduction and/or increased incidence of chronic
kidney disease (CKD).[3–6]Moreover, cumulative TDF exposure has been associated with
reduced bonemineral density and increased osteoporotic fracture risk.[7]
TDF-related renal toxicity seems to be enhanced by concurrent administration of ritonavir-
boosted protease inhibitors (PI/r), particularly atazanavir/ritonavir (ATZ/r) and lopinavir/rito-
navir (LPV/r).[4, 8, 9] Similarly, a steeper increase in bone resorptionmarkers and more
marked reduction in bone mineral density were observed in three randomized clinical trials,
when TDF was associated with a PI/r.[10–12]
Toxicity leading to discontinuation of TDF is a rare occurrence, in clinical trials, ranging
from 0 to 3% by 2 years from starting the drug.[13–18]Nonetheless, in clinical practice, the
proportion of TDF discontinuations due to toxicity or side effects seems to be higher, but it
remains largely unexplored.
The aim of our study was to describe the use of TDF as part of first-line ART initiated from
ART-naïve in clinical practice, to assess the rate of its discontinuation over time and to explore
factors associated with the risk of TDF discontinuation (with the focus on the drug class of the
third drug initiated with TDF).
Methods
Data from the Icona Foundation Study database were used. A detailed description of the cohort
has been provided elsewhere.[19, 20] In brief, the ICONA Foundation Study is an Italian multi-
centre prospective observational cohort study of HIV-1-positive persons enrolled since 1997.
This cohort consists of more than 12,000 patients, recruited in 71 infectious disease units in
Italy, 41 of which still provide new enrolments and updated follow-up of the persons enrolled.
Eligible patients are those who, for whatever reason, were naive to antiretroviral drugs at the
time of enrolment. Demographic, pre-enrolment, clinical and laboratory data and information
on the specific therapies are collected for all participants and recorded online. Reasons (up to
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three) for discontinuing drugs according to the treating physician are also reported on a stan-
dardized case report form. Only the main reason for discontinuation per antiretroviral drug
was used in the analysis. All data are updated at the occurrence of any clinical event and, in the
absence of such an event, at least every 6 months.
Patients from the ICONA Foundation Study were included in the present analysis if they
had initiated a TDF-containing regimen together with a non-nucleoside reverse transcriptase
inhibitors (NNRTI) or a PI/r while naïve to antiretrovirals, between January 1st 2003 and June
30th 2014, and they had been treated with TDF for>30 days. Patients who ever tested positive
for hepatitis B surface antigen over follow-up were excluded. This was done because persistence
on TDF treatment, despite toxicities, was assumed to be higher among those with hepatitis B
co-infection than among HIVmonoinfected patients. Follow-up accrued from the date of TDF
initiation up to its discontinuation or to the last recorded clinical visit. The reasons for TDF
discontinuation, as reported by the treating physicians, was used to classify the interruptions.
The primary outcome was TDF discontinuation regardless of the cause. Secondaryoutcome
measure was TDF discontinuation due to toxicity, as reported by the treating physician. In the
secondary outcome analysis, follow up was truncated at the date of last clinical visit if a person
had discontinued for a reason different from toxicity. This was done becausewe were interested
in predicting how many people stopped TDF due to toxicity. We used the marginal risk which
reflects both the causal effect of covariates on the risk of stopping TDF because of toxicity but
also other possible mechanisms related to the competing events (e.g., interruptions for other
causes which were not relevant here). The analysis of the risk of interruption due to toxicity
was further restricted to only discontinuations due to renal toxicity, again using a marginal
model approach and classifying the reason for discontinuation according to the reason
reported by the treating physician. Eventually, all analyses were repeated considering only
selective TDF discontinuations (TDF interruption or substitution, while maintaining
unchanged the remaining antiretroviral treatment) as the outcome of interest, in order to mini-
mize the possible effect of the companion drugs’ side effects on the decision to interrupt TDF.
So, this analysis is designed to evaluate the rate of treatment discontinuation truly attributable
to TDF and not to other drugs. In all analyses, changes in formulation and interruptions fol-
lowed by re-initiation of TDF-based regimens within 1 month and/or TDF discontinuations in
the context of a complete ART discontinuation lasting>1 month did not count as events.
Survival analysis using Kaplan Meyer (KM) and Cox proportional hazards model were
used. An intention-to-treat (ITT) approach, ignoring switches of PI/r, NNRTI or other nucleo-
side reverse transcriptase inhibitors (NRTI), was performed. Besides the drug class co-adminis-
trated with TDF (PI/r vs. NNRT), the following covariates were included in the multivariable
Coxmodel: demographics, mode of HIV transmission, hepatitis C coinfection (defined as
serum reactivity for hepatitis C virus antibody), baseline eGFR (calculated using the CKD-Epi
formula) [21] and CD4+ T-cell count, diagnosis of diabetes, lipid assessment (total cholesterol
and HDL cholesterol), use of blood pressure lowering drugs and statins, calendar year. These
were chosen a priori as potentially associated with both the choice of the initial class of the
third drug and the risk of stopping TDF. Cox regression models were stratified by clinical site.
Finally we estimated the variation of eGFR over time since TDF initiation and whether it
was different according to third-drug class used (PI/r or NNRTI), using a mixed linear model
with random intercept and slope. This was done to supplement the main analysis based on the
reason reported by the clinician which is likely to be a less objective endpoint influenced by
beliefs engrained in clinical practice.
All statistical analyses were performed using SAS 9.4 statistical software (SAS Institute Inc.,
Cary, NC, USA, 2014). All P-values presented are two sided and a P-value <0.05 indicated con-
ventional statistical significance.
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Results
Patients’ characteristics
Three thousands six hundred and eighteenHIV-positive patients were enrolled and followed
for a total of 8,043 patient-years of follow-up. One thousand six-hundred sixty-nine patients
(46%) started TDF as part of a NNRTI- based regimen and the remaining 1,949 (54%) a PI/r
based regimen. Their median age was 38 years-old and their median baseline eGFR was 106
ml/min. Patients on PI/r based regimen were more likely to be female (p<0.001), older
(p = 0.02) and previously diagnosedwith AIDS (p<0.001) and to have a lower CD4-T cell
count (p<0.001) and a higher HIV viral load (p<0.001, Table 1). Among patients on PI/r
based regimen, 783 (40%) were on ATZ/r, 676 (35%) were on darunavir/ritonavir (DRV/r) and
490 (25%) were on LPV/r. Patients who started TDF as a part of a integrase- inhibitor based
regimen were only 8, and we decided not to include them in the analysis. A detailed description
of the characteristics of the patients is shown in Table 1.
Risk of tenofovir discontinuation
A total of 277 cases of TDF discontinuation were observed, of whom 202 in PI/r group and 75
in NNRTI group, respectively. The probability of discontinuation of TDF regardless of the rea-
son was of 7.4% (95% CI: 6.4–8.5) by 2 years and 14.1% (95%CI 12.2–16.1) by 5 years. When
patients were grouped according to the third-drug class started with TDF, the 5- year KM esti-
mates of TDF discontinuation were 7.6% (95%CI: 5.5–9.7)) and 20.4% (95%CI 17.2–23.6) in
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the NNRTI and PI/r group, respectively (log-rank p<0.001) (Fig 1). Among the 277 patients
who stopped TDF, 123 (44.4%) switched to an abacavir/lamivudine-containing regimen, 50
(18%) to a regimen containing the sole lamivudine or emtricitabine, 29 (10.5%) to a
Table 1. Characteristics of the patients initiatinga tenofovir-containing regimen, grouped by “third drug” class.
Characteristics Third-drug class p-value Total
N = 3618
NNRTI PI/r
N = 1669 N = 1949
Gender, n (%)
Female 296 (17.7%) 440 (22.6%) <0.001 736 (20.3%)
Mode of HIV transmission, n (%)
Intravenous drug use 148 (8.9%) 209 (10.8%) 357 (9.9%)
Homosexual contacts 723 (43.5%) 721 (37.1%) 1444 (40.1%)
Heterosexual contacts 667 (40.0%) 858 (44%) 1525 (42.2%)
Other/unknown 124 (7.5%) 154 (7.9%) 0.001 278 (7.7%)
Ethnicity, n (%)
Black 85 (5.1%) 151 (7.7%) 0.001 236 (6.5%)
AIDS diagnosis, n (%)
Yes 69 (4.1%) 146 (7.5%) <0.001 215 (5.9%)
NRTIs, n (%)
FTC 1536 (92%) 1869 (95.9%) 3405 (94.1%)
3TC 115 (6.9%) 54 (2.8%) 169 (4.7%)
Other 18 (1.1%) 26 (1.3%) <0.001 5 (0.1%)
HCVAb, n (%)
Negative 798 (47.8%) 725 (37.2%) 1523 (42.1%)
Positive 130 (7.8%) 127 (6.5%) 257 (7.1%)
Not tested 741 (44.4%) 1097 (56.3%) 0.817 1838 (50.8%)
Age, years
Median (IQR) 37 (31,43) 38 (32,45) 0.020 38 (32,44)
CD4, count, cells/mmc
Median (IQR) 330 (235,419) 253 (110,372) <0.001 296 (165,397)
CD4 count nadir, cells/mmc
Median (IQR) 311 (218,396) 243 (105,353) <0.001 280 (154,378)
CD8 count, cells/mmc
Median (IQR) 907 (656,1256) 824 (550,1210) <0.001 866 (592,1233)
Viral load, log10 copies/mL
Median (IQR) 4.60 (4,5.09) 4.90 (4.18,5.43) <0.001 4.74 (4.07,5.25)
Follow-up, months
Median (IQR) 19 (7,41) 19 (6,34) 0.012 19 (6,36)
Time from enrollment to date of startingantiretroviral treatment,months
Median (IQR) 2 (0,18) 1 (0,4) <0.001 1 (0,11)
Calendar year of baseline
Median (IQR) 2011 (2009–2013) 2011 (2010–2012) 0.817 2011 (2009–2012)
eGFR (CKD-epi formula), ml/min
Median (IQR) 105.9 (93.77,115.4) 106.5 (93.50, 116.5) 0.369 106.2 (93.62–116.2)
List of abbreviations: 3TC, lamivudine; AIDS, acquired immune deficiency syndrome; CKD-epi, chronic kidney disease epidemiology collaboration [21];
eGFR, estimated glomerular filtration rate; FTC, emtricitabine; HCVAb, hepatitis C virus antibodies; HIV, human immunodeficiency virus; IQR, interquartile
range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor;PI/r, ritonavir-boosted protease inhibitor
doi:10.1371/journal.pone.0160761.t001
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zidovudine/lamivudine-containing regimen, 2 to other NRTI-combinations and 64 (23.1%) to
NRTI-sparing combinations. A detailed description of the composition of the regimen started
after the discontinuation according to the initial third drug is depicted in Table 2.
A multivariable Cox regression analysis assessing time fixed factors at baseline associated
with the risk of TDF discontinuation was run (full results in Table 3A). In this model, initiation
of a PI/r-based treatment was associated with a significantly higher risk of TDF discontinuation
Fig 1. Kaplan-Meier estimates of risk of tenofovir discontinuation regardless of the reason in boostedprotease inhibitors
versus non-nucleoside reverse transcriptase inhibitors groups.
doi:10.1371/journal.pone.0160761.g001
Table 2. Composition of the NRTI back-bone of the regimenstartedafter the discontinuation of tenofovir (rows), according to the initial third drug
(columns)–All tenofovir discontinuations.
Regimen started
New regimen after stop of TDF TDF/FTCor TDF/3TC
plus
Efavirenz Nevirapine Lopinavir Atazanavir Darunavir Any drug
NRTI-sparing regimen 12 0 25 17 10 64 (23.1%)
Abacavir/lamivudine 31 5 37 27 23 123 (44.4%)
Zidovudine/lamvudine 15 1 6 5 2 29 (10.5%)
Lamivudine or emtricitabine only 4 0 5 28 13 50 (18.1%)
Didanosine ± lamivudine or emtricitabine 6 0 3 0 0 9 (3.2%)
Other NRTI combinations 1 0 0 1 0 2 (0.7%)
Total 69 (24.9%) 6 (2.2%) 76(27.4%) 78 (28.2%) 48 (17.3%) 277 (100%)
doi:10.1371/journal.pone.0160761.t002
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(HR 1.70; 95%CI 1.16–2.48).Moreover, a lower eGFR at ART initiation was an additional inde-
pendent risk factor (per 10 ml/min decrease,HR 1.19; 95%CI 1.08–1.32). Among patients start-
ing a PI/r-based regimen, the hazard of TDF discontinuation did not differ to a significant
extent comparing the different PI/r (HR 0.99; 95%CI 0.66–1.48 and HR 1.57; 95%CI 0.9–2.73,
for use of ATV/r and DRV/r versus LPV/r, respectively).
Reasons for tenofovir discontinuation and risk of toxicity-driven
discontinuation
A half (n = 139, 50.2%) of the discontinuations were driven by toxicity. Among these, 78/139
(56.1%) were motivated by renal toxicity (64 patients) or by osteopenia/osteoporosis (14 patients).
Interruptions due to toxicity accounted for 31% (43/139) and 69% (96/139) of the discontinuations
among patients who started PI/r and NNRTI, respectively. The other reasons for TDF discontinua-
tion reported by the treating physician were non-adherence (7.6%%), simplification (15.5%), failure
(11.2%), and other/unknowncauses (11.2%). The 5- year KM estimates of TDF discontinuation
due to toxicity were 10.7% (95%CI: 8.1–13.4) vs. 4.7% (95%CI: 2.9–6.5) for discontinuation due to
toxicity in the PI/r and NNRTI group, respectively (Log-rankp = 0.0001) (Fig 2).
Table 3. (a,b,c)Multivariable Cox regression analysis assessing factors associatedwith tenofovir discontinuation regardless of the reason,
becauseof toxicity andwith selective tenofovir discontinuation.
Crude and adjusted relative hazards
Outcomes CrudeRH (95%CI) p-value Adjusted*RH (95%CI) p-value
(A) Discontinuationof tenofovir regardless of the reason
DrugClass
NNRTI 1.00 1.00
PI 2.50 (1.91–3.26) <0.001 1.70 (1.16–2.48) 0.006
Baselineweight,Kg
per 10 heavier 0.94 (0.84–1.05) 0.263 0.95 (0.81–1.11) 0.534
Baseline eGFR,ml/min
per 10 lower 1.18 (1.10–1.27) <0.001 1.19 (1.08–1.32) < .001
(B) Discontinuation of tenofovir due to toxicity
DrugClass
PI/r 1.00 1.00
NNRTI 2.04 (1.42–2.93) <0.001 1.58 (0.93–2.70) 0.093
Age, years
per 10 older 1.60 (1.34–1.90) <0.001 1.43 (1.11–1.85) 0.005
Calendar year
per more recent year 1.12 (1.03–1.22) 0.010 1.14 (1.00–1.31) 0.059
Baseline eGFR,ml/min
per 10 lower 1.32 (1.21, 1.45) <0.001 1.24 (1.08, 1.42) 0.002
(C) Selective discontinuation of tenofovir
DrugClass
PI/r 1.00 1.00
NNRTI 3.93 (2.56, 6.05) <0.001 2.77 (1.49, 5.12) 0.001
* adjusted for age, gender, black ethnicity, mode of HIV transmission, weight, hepatitis C co-infection status, AIDS diagnosis, baseline CD4+ count and
nadir, viral load at cART initiation, year of startingcART, diabetes, use of blood pressure lowering drugs at baseline, baseline eGFR and stratified by clinical
center.
eGFRwas calculated using the chronic kidney disease epidemiology collaboration formula. [21]
List of abbreviations: cART, combination antiretroviral treatment;CI, confidence interval; eGFR, estimated glomerular filtration rate; NNRTI, non-nucleoside
reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor; RH, relative hazard.
doi:10.1371/journal.pone.0160761.t003
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In a multivariable Cox regression analysis, initiating treatment with PI/r (compared with
starting a NNRTI, HR 1.58; 95%CI 0.93–2.70), older age (per 10 years increase, HR 1.43; 95%
CI 1.11–1.85) and lower baseline eGFR (per 10 ml/min decrease, HR 1.24; 95%CI 1.08–1.42)
were independent predictors of TDF discontinuation due to toxicity (Table 3B). When discon-
tinuation due to kidney toxicity was used as outcome measure of a separate Cox regression
analysis, drug companion was not associated with the risk of TDF discontinuation (HR 1.31 of
PI/r vs. NNRTI; 95%CI 0.58–2.98) and a lower baseline eGFR was the only independent pre-
dictor of TDF discontinuation (per 10 ml/min decrease, HR 1.46; 95%CI 1.21–1.76).
When a mixed linear model was used to estimate average eGFR trajectories, people who had
started TDF co-administeredwith a PI/r, rather than a NNRTI, had a steeper eGFR reduction
over time, but the difference was not statistically significant (mean change in eGFR per year in
the PI/r group: -1.5; 95%CI [-1.9;-1.2] vs.–mean change in the NNRTI group: -1.2; 95%CI
[-1.7;-0.70], p = 0.32).
Selective tenofovir discontinuations
One hundred and thirty-six selective TDF discontinuations were observedduring the study fol-
low-up. After selective TDF discontinuation, 75 (55.2%) patients switched to an abacavir/lami-
vudine-containing regimen, 34 (25%) to a regimen containing the sole lamivudine or
emtricitabine, 8 (5.9%) to a zidovudine/lamivudine-containing regimen, 1 (0.7%) to other NRTI-
Fig 2. Kaplan-Meier estimates of risk of tenofovir discontinuationdue to toxicity in boostedprotease inhibitorsversus non-
nucleoside reverse transcriptase inhibitorsgroups.
doi:10.1371/journal.pone.0160761.g002
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combinations and 13 (9.6%) to NRTI-sparing combinations. A detailed description of the compo-
sition of the regimen started after the discontinuation according to the initial third drug is
depicted in Table 4. The 5 year KM estimates in the PI/r vs. NNRTI group are illustrated in Fig 3.
Using multivariable Cox regression analysis, initiation of PI/r (HR 2.77 vs. starting a NNRTI; 95%
CI 1.49–5.12) was the only independent predictor of selective TDF discontinuation (Table 3C).
Discussion
In our study a non-negligible proportion of naïve patients, initiating TDF as part of their first
antiretroviral regimen started when they were ART-naive, underwent discontinuation of the
drug.We found that the probability of TDF discontinuation by 2 years of treatment was 7.4%
and, in 50% of our participants, the main reason leading to discontinuation was toxicity. By 5
years, 14.1% of patients had discontinued TDF. These rates were significantly higher than
those reported in previous randomized controlled studies in patients using TDF, in which the
proportion of toxicity events leading to discontinuation ranged from 0 to 3% by 2 years from
starting the drug.[13–18, 22] There may be multiple reasons for this apparent discrepancy.
Patients with pre-existing kidney disease or with risk factors for TDF-associated renal
impairment, such as cardiovascular or metabolic diseases, concomitant nephrotoxic medica-
tions, low body weight, advanced age and lower CD4 cell count are typically under-represented
in clinical trials.[22] There is an issue with this as patients in trials are different from those seen
in clinical practice, who are aging populations, with advanced HIV infections and multiple
comorbidities.Moreover, treating physicians could be more prone to modify treatment in the
clinical setting than during trials. In clinical practice, there are less restriction to switching than
in some of the trials and if there are prior beliefs among clinicians that a drug is likely to drive a
specific toxicity the appearance of one of these may lead to early treatment interruptions or
drug switches, even in presence of only mild, not clinically significant side effects, such as initial
GFR reduction or bone mineral density loss. Similarly, unconventional less-drug regimens,
such as NRTI-sparing or dual therapies with lamivudine, used in 23% and 18% of patients dis-
continuing TDF in our cohort, respectively, might have been pursued by clinicians in the
attempt of both reducing costs and preventing long-term drug toxicities.
Nevertheless, our results prove that TDF was maintained as part of ART regimens in the
majority of patients, for a period of observation of>5 years. Discontinuation rates of TDF
appear to be still lower than those reported for other drugs. Previous observational studies
reported rates of discontinuation after 2 year of more than 30%, for third-drugs [23] and for
abacavir/lamivudine.[24]Consistently with these results, a study on determinants of
Table 4. Composition of the NRTI back-bone of the regimenstartedafter the discontinuation of tenofovir (rows), according to the initial third drug
(columns)–Selective tenofovir discontinuations.
Regimen started
New regimen after stop of TDF TDF/FTCor TDF/3TC
plus
Efavirenz Nevirapine Lopinavir Atazanavir Darunavir Any drug
NRTI-sparing regimen 0 0 5 2 6 13 (9.6%)
Abacavir/lamivudine 17 3 17 19 19 75 (55.1%)
Zidovudine/lamivudine 2 0 5 1 0 8 (5.9%)
Lamivudine or emtricitabine only 0 0 2 21 11 34 (25%)
Didanosine ± lamivudine or emtricitabine 4 0 1 0 0 5 (3.7%)
Other NRTI combinations 0 0 0 1 0 1 (0.7%)
Total 23 (16.9%) 3 (2.2%) 30 (22.1%) 44 (32.3%) 36 (26.5%) 136 (100%)
doi:10.1371/journal.pone.0160761.t004
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modification of the first ART in a large cohort of European and North American patients sug-
gested that TDF/emtricitabine had the lowest rate of switch/change and interruption, compared
to zidovudine/lamivudine, abacavir/lamivudine and other backbone combinations.[25] All
together, these findings support current guidelines indicating TDF as component of most sug-
gested first-line ARV regimens, based on its high potency and safety profile.[26] In our study, co-
administration with a PI/r was consistently associatedwith higher rates of TDF discontinuation,
regardless of the chosen endpoint (although the differencewas not statistically significant when
the discontinuation due to renal toxicity was taken into account, mainly because of the lack of
power of this secondary analysis). This finding seems to be supported by biological evidence. Pre-
vious studies have suggested that PI/r could slow TDF renal clearance and increase its plasma
and renal tubular intracellular concentrations, via different mechanisms, including a blockage of
the tubular renal transporter of TDF (the multidrug resistance associated proteins), P-glycopro-
tein activity inhibition and an increased intestinal absorption.[27, 28] As a possible consequence,
higher rates of renal toxicity due to TDF, when associatedwith PI/r, have been shown in several
studies.[4, 8, 9, 11] Of note, no significant differences were found when different PI/r were com-
pared to each other. All together, these finding suggest that durability of TDF-containing treat-
ment may depend on its companions and that use of PI/r should be evaluated with caution in
patient with other risk factors for TDF premature discontinuation and/or toxicity.
On the other hand, when we specifically investigated creatinine, no significant differences in
term of eGFR decline was found comparing patients treated with TDF in combination with
Fig 3. Kaplan-Meier estimates of risk of selective tenofovir discontinuation in boostedprotease inhibitorsversus non-
nucleoside reverse transcriptase inhibitorsgroups.
doi:10.1371/journal.pone.0160761.g003
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PI/r or NNRTI. Of interest, the effect was in the expecteddirectionwith people who initiated a
PI/r showing a higher initial level of eGFR and a steeper slope of decline over follow-up when
compared to those starting a NNRTI. Moreover, when discontinuation due to renal toxicity
alone was considered as the outcome, no difference in rate of discontinuation was found between
PI/r and NNRTI recipients. These findings suggest that, in clinical practice, TDF discontinua-
tions is driven by parameters other than eGFR alone. Indeed, renal function assessment is likely
to include also other parameters (such as proteinuria or phosphate level), which were not avail-
able in our database. Moreover, other causes, related or not related with direct drug toxicity, can
bemore important in the decision of TDF discontinuation. Nevertheless, we cannot exclude that
the observed increased risk in the PI/r group could be due to treating clinicians’ beliefs regarding
the interaction betweenTDF and PI/r or other unmeasured confounding.
Not surprisingly, the risk of TDF discontinuation due to toxicity and renal toxicity was
higher among patients with a lower eGFR at baseline, in accordance with the results of a previ-
ous study.[5] When other options are available, use of TDF should be avoided in those with
compromised renal function before treatment initiation.
Our study has some limitations that merit to be acknowledged.First, as mentioned above, this is
a comparison in the observational setting so that confounding is likely to be an issue. Second, the
reasons for TDF discontinuation are those reported by the physician and therefore subjective by
definition.Clinicians’ strategiesmay also vary by clinical sites (although Coxmodels were stratified
by site). Moreover, only themain reason of discontinuation was taken into account, although only
in seven cases a secondary reason for TDF discontinuation was reported, thus it is unlikely to have
influencedour results. Third, there was a high percentage of unknown/other causes of discontinua-
tion which is difficult to handle in the statistical analysis without making some strong assumptions.
Fourth, as alreadymentioned, renal functionwas evaluated basing solely on eGFR and other mark-
ers of renal damage, such as urine dip stick analysis, phosphatemia or glycosuria,were not available.
Fifth, due to the study time-frame, in this analysis we were not able to explore the rate of TDF dis-
continuation when it is prescribed in associationwith integrase inhibitors or coformualted with ril-
pivirine, because these regimens were introduced inmore recent years.
In conclusion, our study had showed that frequency of TDF discontinuation in clinical prac-
tice is relatively low but much higher than that estimated in clinical trials. The co-administra-
tion of TDF with PI/r versus NNRTI and lower eGFR at initiation of the TDF-based regimen
were independently associated with a higher risk of TDF discontinuation but discontinuation
of TDF due to toxicity might be driven by parameters other than eGFR alone. Further studies
are needed to clarify the possible interaction betweenTDF and the PI/r class which may lead to
renal toxicities in patients with HIV treated with these drugs.
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